N,N-diethyl-2-[6-(phenylsulfonyl)imidazo[1,2-a]-pyridin-2-yl]ethanamine | 1428761-49-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N,N-diethyl-2-[6-(phenylsulfonyl)imidazo[1,2-a]-pyridin-2-yl]ethanamine
• 英文别名: N,N-diethyl-2-[6-(phenylsulfonyl)imidazo[1,2-a]pyridin-2-yl]ethanamine；2-[6-(benzenesulfonyl)imidazo[1,2-a]pyridin-2-yl]-N,N-diethylethanamine
• CAS: 1428761-49-2
• 化学式: C₁₉H₂₃N₃O₂S
• 分子量: 357.477
• InChiKey: VGZSGYDUFMAAHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  63.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-[2-(6-bromoimidazo[1,2-a]pyridin-2-yl)ethyl]-1Hisoindole-1,3(2H)-dione 在 bis-triphenylphosphine-palladium(II) chloride 、 四(三苯基膦)钯 、 三乙酰氧基硼氢化钠 、 一水合肼 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 70.0h， 生成 N,N-diethyl-2-[6-(phenylsulfonyl)imidazo[1,2-a]-pyridin-2-yl]ethanamine
  参考文献：
  名称：

  Exploring 6-(substituted sulfonyl)imidazopyridines as a potential scaffold for the design of 5-HT6 ligands

  摘要：

  Cognitive dysfunction is a characteristic of various forms of dementia such as Alzheimer's disease. We have focused on the 5-HT6 receptor in order to identify potent ligands. Herein we report the design of a novel series of 6-sulfonylimidazole derivatives substituted with an alkylamino chain at the 2- or 3-position, their synthesis, and their ability to interact with 5-HT6 receptors as evaluated in radioligand binding assays.

  DOI：

  10.1007/s00706-012-0893-3

文献信息

• Exploring 6-(substituted sulfonyl)imidazopyridines as a potential scaffold for the design of 5-HT6 ligands
  作者：Valeria Moas Heloire、Christophe Furman、Patricia Melnyk、Pascal Carato

  DOI：10.1007/s00706-012-0893-3

  日期：2013.3

  Cognitive dysfunction is a characteristic of various forms of dementia such as Alzheimer's disease. We have focused on the 5-HT6 receptor in order to identify potent ligands. Herein we report the design of a novel series of 6-sulfonylimidazole derivatives substituted with an alkylamino chain at the 2- or 3-position, their synthesis, and their ability to interact with 5-HT6 receptors as evaluated in radioligand binding assays.